Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

8:23 AM ET 10-Q
Financial Results Frp Holdings, Inc. FRPH

Frp Holdings Q3 2026 Results: Net Loss of $165K

FRP Holdings, Inc. reported a net loss of $1.11 million for the nine months ended September 30, 2026, compared to a net income of $2.95 million in the prior year period. The decline was driven by increased general and administrative expenses and higher equity losses from joint ventures, despite a slight increase in total revenues to $32.64 million.

Key figure
Net loss $165K
8:23 AM ET 10-Q
Financial Results Benitec Biopharma Inc. BNTC

Benitec Biopharma Q1 2026 Results: Net Loss of $12.9M, Loss Widens

Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.

Key figure
Net loss $12.9M
8:18 AM ET 8-K
Financial Results Quantum Cyber N.V. QUCY

Quantum Cyber Financial Results

Quantum Cyber reported its first revenue of approximately $1.0 million for Q3 2026 following its strategic pivot to autonomous defense. The company also announced an $8.0 million funding commitment from CEO David Lazar to support the build-out of its Bridgeport manufacturing facility and technology programs.

Counterparty
David Lazar

“The third quarter of 2026 is the quarter in which Quantum Cyber crossed from a pre-revenue strategy into an operating company. We generated our first revenue, we installed the first production equipment at our Bridgeport facility, and we resolved a legacy legal claim that had overhung our capital structure.”

David Lazar, Chief Executive Officer

“The $8.0 million funding commitment I provided to the Company on November 11, 2026 is intended to reinforce the balance sheet while we complete the build-out of the Bridgeport facility and continue to advance the Project LightShift quantum antenna program under our newly expanded field of use.”

David Lazar, Chief Executive Officer
8:18 AM ET 8-K
Financial Results Aardvark Therapeutics, Inc. AARD

Aardvark Therapeutics Financial Results

Aardvark Therapeutics reported Q3 2026 financial results and announced that the FDA has lifted the clinical hold on its lead candidate ARD-101 for Prader-Willi Syndrome. The company ended the quarter with $60.3 million in cash, which is expected to fund operations through 2027 as it prepares for a clinical development meeting with the FDA in early 2027.

Term
Q3 2026

“The lifting of the clinical hold and the FDA’s agreement that we may conduct an open-label trial at 200 mg twice daily are important steps toward resuming clinical development of ARD-101 in PWS. We have developed a proposed clinical development plan and look forward to discussing it with the FDA. We remain committed to advancing ARD-101 for patients and families affected by PWS.”

Tien Lee, M.D., Founder and Chief Executive Officer
8:17 AM ET 10-Q
Financial Results Fortress Biotech, Inc. FBIO

Fortress Biotech Q3 2026 Results: Net Loss of $5.84M

Fortress Biotech reported a significant net income of $129.5 million for the nine months ended September 30, 2026, primarily driven by a $158.9 million gain on the sale of a priority review voucher. This represents a substantial turnaround from the $27.5 million net loss in the prior year period, while total assets grew to $280.2 million.

Key figure
Net loss $5.84M
8:15 AM ET 8-K
Financial Results Cineverse Corp. CNVS

Cineverse Financial Results

Cineverse reported Q2 FY 2027 revenue of $26.0 million, a 110% year-over-year increase driven by its technology and media services segments. The company achieved net income of $3.2 million and its third consecutive quarter of positive Adjusted EBITDA, while reaffirming full-year revenue guidance of $115 million to $120 million.

Term
Q2 FY 2027
8:13 AM ET 8-K
Financial Results Titan International Inc TWI

Titan International Financial Results

Titan International provided supplemental historical financial information for the first and second quarters of 2026 and 2025, recast to reflect its ITM business as discontinued operations following a sale agreement. The filing includes formal GAAP income statements for these periods to assist investors in evaluating the company's continuing operations.

Term
Q2 2026
8:11 AM ET 8-K
Financial Results Biofrontera Inc. BFRI

Biofrontera Financial Results

Biofrontera Inc. reported Q3 2026 net product revenue of $9.1 million, a 30% year-over-year increase driven by its photodynamic therapy products. The company achieved a significant regulatory milestone with the FDA approval of Ameluz for the treatment of superficial basal cell carcinoma. Net loss for the quarter narrowed slightly to $6.4 million compared to $6.6 million in the prior-year period.

Term
Q3 2026

“The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp.”

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
8:09 AM ET 10-Q
Financial Results DeltaSoft Corp DSFT

DeltaSoft Q2 2026 Results: Net Loss of $5.38K, Loss Narrows

DeltaSoft Corp. reported a net loss of $15,113 for the six months ended September 30, 2026, on revenues of $11,299. The company is in the development stage with an accumulated deficit of $16,022 and faces a going concern uncertainty due to limited working capital and reliance on future investment capital.

Key figure
Net loss $5.38K
8:07 AM ET 10-Q
Financial Results Medalist Diversified, Inc. MDRR

Medalist Diversified Q3 2026 Results: Turns Profitable, Net Income $4.64M

Medalist Diversified, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $20.96 million compared to a net loss of $1.59 million in the prior year, primarily driven by a $21.19 million gain on the disposal of investment properties. Total assets decreased from $77.74 million to $52.29 million as the company shifted its portfolio, including a substantial increase in marketable securities and a reduction in mortgage debt.

Key figure
Net income $4.64M
8:06 AM ET 8-K
Financial Results Owlet, Inc. OWLT

Owlet Financial Results

Owlet reported Q3 2026 revenue of $30.4 million and achieved positive net income of $1.4 million, driven by gross margin expansion and growth in its subscription service. However, the company withdrew its full-year 2026 financial outlook due to a safety update for its camera cable guard accessory, which is expected to cause retail sales interruptions and remediation expenses in Q4.

Term
Q3 2026

“We delivered a strong third quarter, driven by our focus on profitable growth. Revenue of $30.4 million was in line with our expectations, we expanded gross margin by 315 basis points, generated positive operating income and operating cash flow, and delivered $3.5 million of Adjusted EBITDA.”

Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder

“Today, we initiated a camera cable guard safety update for the cable guard accessory. We are providing a replacement enclosed cable guard system that we believe delivers on our commitment to elevating safety standards in the market.”

Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder
8:06 AM ET 10-Q
Financial Results Allarity Therapeutics, Inc. ALLR

Allarity Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens

For the nine months ended September 30, 2026, Allarity Therapeutics reported a net loss of $12.4 million, an increase from the $7.9 million loss in the prior year period, primarily driven by higher research and development costs. The company's total stockholders' equity turned to a deficit of $2.3 million as of September 30, 2026, while cash and restricted cash increased to approximately $24.1 million.

Key figure
Net loss $6.2M
8:06 AM ET 8-K
Financial Results Fortress Biotech, Inc. FBIO

Fortress Biotech Financial Results

Fortress Biotech reported Q3 2026 financial results with total net revenue increasing 9% year-over-year to $19.2 million. During the quarter, the company repaid its Oaktree credit facility in full, leaving it with no outstanding debt at the parent level, and in-licensed FB-607 for the treatment of IBS-D.

Term
Q3 2026

“The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”).”

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer

“With our growing royalty income from ZYCUBO® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
8:05 AM ET 8-K
Financial Results PAVmed Inc. PAVM

PAVmed Financial Results

PAVmed reported preliminary Q3 2026 financial results, highlighted by its subsidiary Lucid Diagnostics securing nationwide Medicare reimbursement for the EsoGuard test. The company reported $1.2 million in revenue for the quarter and noted that October saw record test volume of over 1,800 tests.

Term
Q3 2026

“We’re very encouraged by developments across the PAVmed portfolio. Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid’s largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer
8:05 AM ET 8-K
Financial Results PDS Biotechnology Corp PDSB

PDS Biotechnology Financial Results

PDS Biotechnology reported third quarter 2026 financial results, highlighting a strategic shift to PDS0301 as its lead development program. The company also noted the initial closing of a $22.3 million PIPE financing led by Nant Capital and the appointment of several new board members, including Dr. Patrick Soon-Shiong.

“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program. We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”

Frank Bedu-Addo, PhD, President and Chief Executive Officer
8:03 AM ET 8-K
Financial Results Benitec Biopharma Inc. BNTC

Benitec Biopharma Financial Results

Benitec Biopharma reported financial results for its first fiscal quarter ended September 30, 2026, and announced a change in its fiscal year-end from June 30 to December 31. The company highlighted a 100% responder rate in its ongoing Phase 1b/2a study of BB-301 for OPMD and confirmed it remains on track to begin a pivotal trial in mid-2027.

Term
Q1 2027

“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”

Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
8:01 AM ET 8-K
Financial Results Immunic, Inc. IMUX

Immunic Financial Results

Immunic, Inc. reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate, vidofludimus calcium. The company remains on track to report top-line data from its pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis in December 2026, which could support a potential NDA submission.

Term
Q3 2026

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history. We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS.”

Erik Lundgren, Chief Executive Officer of Immunic

“Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive.”

Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
8:01 AM ET 10-Q
Financial Results TuHURA Biosciences, Inc. HURA

TuHURA Biosciences Q3 2026 Results: Net Loss of $6.41M, Loss Narrows

TuHURA Biosciences reported a net loss of $23.2 million for the nine months ended September 30, 2026, compared to a $23.3 million loss in the prior year. The company significantly increased its total assets to $36.2 million, primarily through the capitalization of $6.9 million in revolving credit facility debt issuance costs and $2.9 million in prepaid R&D expenses.

Key figure
Net loss $6.41M
7:53 AM ET 10-Q
Financial Results Verrica Pharmaceuticals Inc. VRCA

Verrica Pharmaceuticals Q3 2026 Results: Net Loss of $12.4M, Loss Widens

Verrica Pharmaceuticals reported a net loss of $35.2 million for the first nine months of 2026, driven by increased R&D and SG&A expenses. The company issued a going concern warning due to an accumulated deficit of $360.2 million and limited cash reserves of $14.4 million, though it recently secured a credit agreement for up to $27.5 million.

Key figure
Net loss $12.4M
7:52 AM ET 10-Q
Financial Results Yarrow Bioscience, Inc. YARW

Yarrow Bioscience Q3 2026 Results: Net Loss of $9.72M

Yarrow Bioscience, Inc. reported a net loss of $9.7 million for the third quarter of 2026, driven by $10.7 million in operating expenses. Following a merger, the company significantly strengthened its balance sheet, ending the period with $268.9 million in cash and cash equivalents compared to $100.0 million at the end of 2025.

Key figure
Net loss $9.72M
7:50 AM ET 8-K
Financial Results TuHURA Biosciences, Inc. HURA

TuHURA Biosciences Financial Results

TuHURA Biosciences reported financial results for the third quarter ended September 30, 2026, and provided updates on its Phase 3 immuno-oncology programs. The company highlighted positive preliminary data from its IFx-2.0 study in Merkel cell carcinoma and received FDA clearance to begin a Phase 1b study for its VISTA-inhibiting antibody, TBS-2025. Management noted that operations remain funded through a $50 million credit facility from its largest shareholder.

Term
Q3 2026

“We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda® in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months.”

Dr. James Bianco, President and Chief Executive Officer

“With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events.”

Dr. James Bianco, President and Chief Executive Officer
7:46 AM ET 8-K
Financial Results Noodles & Co NDLS

Noodles & Financial Results

Noodles & Company reported third quarter 2026 financial results, highlighted by a 9.5% increase in system-wide comparable restaurant sales. Despite a 1.0% decrease in total revenue to $120.9 million, the company significantly narrowed its net loss to $2.1 million and expanded its restaurant contribution margin by 350 basis points to 16.7%.

Term
Q3 2026

“We are very excited that our third quarter performance continued our strong sales momentum and margin expansion, underscoring the sustainability of our growth and the impact of the improvements we have made across the business. System-wide comparable sales grew 9.5%, which was our third consecutive quarter above 9.0% and eighth consecutive quarter of positive comparable sales growth.”

Joe Christina, President and Chief Executive Officer

“We have also reduced debt by more than $9.0 million year to date, further strengthening our financial foundation. Our focus remains on making Noodles & Company a more compelling choice for guests and a more profitable business, with disciplined execution that supports durable, outsized long-term growth.”

Joe Christina, President and Chief Executive Officer
7:45 AM ET 8-K
Financial Results Digi Power X Inc. DGXX

Digi Power X Financial Results

Digi Power X reported Q3 2026 revenue of $12.25 million, an 85% increase over the prior quarter, driven by a 400% surge in AI-related revenue. The company ended the period with $119.6 million in cash and digital currencies and expects to close a $200 million credit facility in Q4 2026 to fund its data center expansion.

Term
Q3 2026
7:37 AM ET 8-K
Financial Results Milestone Pharmaceuticals Inc. MIST

Milestone Pharmaceuticals Financial Results

Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.

Term
Q3 2026

“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”

Joseph Oliveto, President and Chief Executive Officer
7:32 AM ET 10-Q
Financial Results Lument Finance Trust, Inc. LFT

Lument Finance Trust Q3 2026 Results: Net Loss of $12.3M

Lument Finance Trust reported a net loss attributable to common stockholders of $13.5 million for the third quarter of 2026, primarily driven by a $16.5 million provision for credit losses and $5.2 million in real estate owned impairment. Total assets decreased to $1.08 billion from $1.22 billion at year-end 2025, while the company executed a 1-for-10 reverse stock split in September 2026.

Key figure
Net loss $12.3M
7:32 AM ET 8-K
Financial Results Twenty One Capital, Inc. XXI

Twenty One Capital Financial Results

Twenty One Capital reported Q3 2026 financial results, highlighted by a net income of $1.087 billion primarily driven by a $1.093 billion fair-value gain on its Bitcoin holdings. The company ended the quarter with 43,514 Bitcoin and $102.8 million in cash while evaluating new business opportunities across the Bitcoin and energy ecosystems.

Term
Q3 2026

“Our mandate is clear: build a durable, cash-generating business around one of the largest corporate Bitcoin treasuries in the world. A balance sheet is not a business. It is our starting point.”

Raphael Zagury, Chief Executive Officer

“We welcome Bitcoin’s appreciation. But gains from an asset we own are not the same as earnings from businesses we operate. Building the latter is our job.”

Raphael Zagury, Chief Executive Officer
7:31 AM ET 10-Q
Financial Results Twenty One Capital, Inc. XXI

Twenty One Capital Q3 2026 Results: Turns Profitable, Net Income $1.09B

Twenty One Capital, Inc. reported a net income of $1.09 billion for the three months ended September 30, 2026, primarily driven by a $1.09 billion gain from the change in fair value of digital assets. However, for the nine-month period, the company recorded a net loss of $186.5 million as digital asset values fluctuated, while maintaining a significant Bitcoin treasury valued at approximately $3.64 billion.

Key figure
Net income $1.09B
7:31 AM ET 10-Q
Financial Results Milestone Scientific Inc. MLSS

Milestone Scientific Q3 2026 Results: Net Loss of $748K, Loss Narrows

Milestone Scientific reported a net loss of approximately $2.5 million for the nine months ended September 30, 2026, an improvement from a $4.6 million loss in the prior year period. Product sales grew slightly to $7.2 million, while the company significantly reduced operating expenses, particularly in research and development and SG&A.

Key figure
Net loss $748K
7:30 AM ET 8-K
Financial Results XTI Aerospace, Inc. XTIA

XTI Aerospace Financial Results

XTI Aerospace reported Q3 2026 revenue of $35.3 million, a 46.1% increase over proforma Q3 2025 results, driven by strong demand in its Drone Nerds business. The company achieved positive Adjusted EBITDA of $1.6 million and completed a strategic pivot by discontinuing its aircraft business and reducing corporate overhead.

Term
Q3 2026

“Our strategic pivot to focus on our Drone Nerds business is substantially complete. We have discontinued the operation of the XTI aircraft business, rightsized our corporate overhead and are focused on the significant opportunity in the commercial and enterprise drone market.”

Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer

“The growth opportunities we see across our portfolio combined with continued disciplined expense management is expected to lead to the transition to positive ongoing operating cash flows during the fourth quarter of 2026.”

Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer
7:30 AM ET 10-Q
Financial Results Jade Biosciences, Inc. JBIO ▶ Call

Jade Biosciences Q3 2026 Results: Net Loss of $35.1M, Loss Widens

Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.

Key figure
Net loss $35.1M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.